These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32025848)

  • 1. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
    Noguchi M; Arai G; Egawa S; Ohyama C; Naito S; Matsumoto K; Uemura H; Nakagawa M; Nasu Y; Eto M; Suekane S; Sasada T; Shichijo S; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2020 May; 69(5):847-857. PubMed ID: 32025848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Tanaka N; Nishimura K; Okajima E; Ina K; Ogawa O; Nagata H; Akakura K; Fujimoto K; Gotoh M; Teramukai S; Hirao Y
    Int J Urol; 2019 Aug; 26(8):797-803. PubMed ID: 31055879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
    Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
    Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.
    Noguchi M; Moriya F; Suekane S; Ohnishi R; Matsueda S; Sasada T; Yamada A; Itoh K
    BMC Cancer; 2013 Dec; 13():613. PubMed ID: 24373380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression.
    Noguchi M; Arai G; Matsumoto K; Naito S; Moriya F; Suekane S; Komatsu N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2015 Apr; 64(4):493-505. PubMed ID: 25662406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study.
    Vermunt MAC; Robbrecht DGJ; Devriese LA; Janssen JM; Thijssen B; Keessen M; van Eijk M; Kessels R; Eskens FALM; Beijnen JH; Mehra N; Bergman AM
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1367. PubMed ID: 33709626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel.
    Noguchi M; Fujimoto K; Arai G; Uemura H; Hashine K; Matsumoto H; Fukasawa S; Kohjimoto Y; Nakatsu H; Takenaka A; Fujisawa M; Uemura H; Naito S; Egawa S; Fujimoto H; Hinotsu S; Itoh K
    Oncol Rep; 2021 Jan; 45(1):159-168. PubMed ID: 33200227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).
    McNeel DG; Chen YH; Gulley JL; Dwyer AJ; Madan RA; Carducci MA; DiPaola RS
    Hum Vaccin Immunother; 2015; 11(10):2469-74. PubMed ID: 26111351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study.
    Saad F; Hussain MHA; Tombal B; Fizazi K; Sternberg CN; Crawford ED; Nordquist LT; Bögemann M; Tutrone R; Shore ND; Belkoff L; Fralich T; Jhaveri J; Srinivasan S; Li R; Verholen F; Kuss I; Smith MR
    Eur Urol; 2024 Oct; 86(4):329-339. PubMed ID: 38644146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
    Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
    Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
    Heath E; Heilbrun L; Mannuel H; Liu G; Lara P; Monk JP; Flaig T; Zurita A; Mack P; Vaishampayan U; Stella P; Smith D; Bolton S; Hussain A; Al-Janadi A; Silbiger D; Usman M; Ivy SP
    Oncologist; 2019 Sep; 24(9):1149-e807. PubMed ID: 31152080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
    Saad F; de Bono J; Shore N; Fizazi K; Loriot Y; Hirmand M; Franks B; Haas GP; Scher HI
    Eur Urol; 2015 Feb; 67(2):223-30. PubMed ID: 25171902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial.
    Tanaka N; Nishimura K; Okajima E; Ina K; Ogawa O; Nagata H; Akakura K; Fujimoto K; Gotoh M; Teramukai S; Hirao Y
    Jpn J Clin Oncol; 2017 Mar; 47(3):247-251. PubMed ID: 28042138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
    Passildas-Jahanmohan J; Eymard JC; Pouget M; Kwiatkowski F; Van Praagh I; Savareux L; Atger M; Durando X; Abrial C; Richard D; Ginzac Couvé A; Thivat E; Monange B; Chollet P; Mahammedi H
    Cancer Med; 2021 Apr; 10(7):2332-2340. PubMed ID: 33666378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
    Armstrong AJ; Saad F; Phung D; Dmuchowski C; Shore ND; Fizazi K; Hirmand M; Forer D; Scher HI; Bono J
    Cancer; 2017 Jun; 123(12):2303-2311. PubMed ID: 28171710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Bilusic M; McMahon S; Madan RA; Karzai F; Tsai YT; Donahue RN; Palena C; Jochems C; Marté JL; Floudas C; Strauss J; Redman J; Abdul Sater H; Rabizadeh S; Soon-Shiong P; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
    Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
    Madan RA; Karzai F; Donahue RN; Al-Harthy M; Bilusic M; Rosner II; Singh H; Arlen PM; Theoret MR; Marté JL; Cordes L; Couvillon A; Hankin A; Williams M; Owens H; Lochrin SE; Chau CH; Steinberg S; Figg WD; Dahut W; Schlom J; Gulley JL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33664086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.